Connect Biopharma (CNTB) Stock Forecast & Price Target

$1.11 +0.12 (+12.12%)

(As of 11/15/2024 ET)

Connect Biopharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 1 Analyst Ratings

Sell
0

Hold
0

Buy
1

Based on 1 Wall Street analysts who have issued ratings for Connect Biopharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for CNTB.

Consensus Price Target

$8.00
620.72% Upside

According to the 1 analysts' twelve-month price targets for Connect Biopharma, the average price target is $8.00. The highest price target for CNTB is $8.00, while the lowest price target for CNTB is $8.00. The average price target represents a forecasted upside of 620.72% from the current price of $1.11.

Get the Latest News and Ratings for CNTB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Connect Biopharma and its competitors.

CNTB Analyst Ratings Over Time

Type	Current Forecast 11/18/23 to 11/17/24	1 Month Ago 10/19/23 to 10/18/24	3 Months Ago 8/20/23 to 8/19/24	1 Year Ago 11/18/22 to 11/18/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$8.00	$8.00	$6.50	$6.00
Forecasted Upside	620.72% Upside	529.92% Upside	470.18% Upside	192.68% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Why buying gold might be a mistake (Ad)

Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.

If you're interested, check out the recording here while the link's still up.

CNTB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CNTB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Connect Biopharma Stock vs. The Competition

Type	Connect Biopharma	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	620.72% Upside	28,534.42% Upside	9.87% Upside
News Sentiment Rating	Positive News See Recent CNTB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/6/2024	HC Wainwright 2 of 5 stars	E. Bodnar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00	+601.75%
9/13/2023	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$5.00	+566.57%
4/12/2023	Leerink Partners 1 of 5 stars	T. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:29 AM ET.

CNTB Forecast - Frequently Asked Questions

: According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Connect Biopharma is $8.00, with a high forecast of $8.00 and a low forecast of $8.00.
: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Connect Biopharma in the last year. There is currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNTB shares.
: According to analysts, Connect Biopharma's stock has a predicted upside of 620.72% based on their 12-month stock forecasts.
: Connect Biopharma has been rated by research analysts at HC Wainwright in the past 90 days.
: Analysts like Connect Biopharma more than other "medical" companies. The consensus rating for Connect Biopharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CNTB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why buying gold might be a mistake (Ad)

If you're interested, check out the recording here while the link's still up.

This page (NASDAQ:CNTB) was last updated on 11/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Connect Biopharma (CNTB) Stock Forecast & Price Target